跳至主要内容
临床试验/NCT05812183
NCT05812183撤回4 期

The Effect of Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Patients with Obesity: a Feasibility Study

University of California, Los Angeles0 个研究点目标入组 40 人开始时间: 2023年7月9日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
撤回
入组人数
40
主要终点
Dyspnea

研究概览

简要总结

Most research to date on bariatric surgery outcomes has been about metabolic syndrome, a disorder very effectively treated by bariatric surgery. However, obesity is also associated with many other problems that have received much less attention. Amongst the most troubling of these for patients is dyspnea. Dyspnea results in substantial patient distress that can greatly reduce health-related quality of life. Little is known about the relationship between dyspnea, weight loss, and bariatric surgery. Dyspnea is a complex symptom that may lead to adaptive responses, such as the need to rest as a consequence of even minimal activity or seeking medical attention. The main outcome of the study will be measured using a new state-of-the-science validated HRQOL measure, the Patient Reported Outcome Measuring Information System for Heart Failure (PROMIS+HF 27).

详细描述

The main purpose of this prospective matched cohort study is to determine the feasibility for a future, novel large-scale study, clinical trial that will aim to determine how common dyspnea is in obese patients, how much dyspnea affects their quality-of-life, and how these parameters are affected by medically or surgically induced weight loss. Our basic assumption is that dyspnea is more common than is commonly believed in obese patients and that it profoundly affects quality of life. Our main hypothesis is that weight loss improves dyspnea and HRQOL and that bariatric surgery induced weight loss is more effective than medical weight loss at improving dyspnea-related quality-of-life.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female ≥18 years of age.
  • All patients undergoing gastric sleeve resection for serious obesity at the Ronald Reagan medical center will be considered for enrollment in the experimental group.
  • English/Spanish speakers.
  • The patients included will be with preserved cognition and a capacity to understand questionnaires.
  • Written informed consent (and assent when applicable) obtained from subject and ability for subject to comply with the requirements of the study.

排除标准

  • Serious cardiovascular disease, previous gastrointestinal surgery, psychological concerns (mental disorders and dementia), recently hospitalized, pulmonary diseases, renal failure, or history of malignancy.
  • Undergoing procedures other than gastric sleeve resection or are having these operations after they have had other bariatric procedures.
  • Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data.

研究组 & 干预措施

Bariatric surgery

Experimental

Gastric sleeve resection will be performed by experienced surgeons. Postoperative care will follow UCLA's postoperative care pathways for gastric sleeve resection.

干预措施: Bariatric surgery (Device)

Medical weight loss

Experimental

The medical weight loss intervention will follow the University of California at Los Angeles's (UCLA) Research For Obesity (RFO) standard protocol. Over a period of 12 months, patients in the medical weight loss group will follow a very loc caloric diet (VLCD) at the UCLA RFO program. All study patients will be prescribed a VLCD, an exercise regimen and will participate in group classes on behavioral modification. The caloric intake consists of a commercially prepared meal replacement powder supplying 700-800 cal/day. Each formula packet provides 100kcal and 15g of high biological value protein, and the daily allowance of required minerals and vitamins.

干预措施: Medical weight loss (Drug)

结局指标

主要结局

Dyspnea

时间窗: 12 months

Will be assessed using the PROMIS+HF 27 will be administered via RedCap for patients both groups. PROMIS+HF 27 is part of a National Institutes of Health initiative to develop state-of-the art measures for quality of life. PROMIS+HF 27 contains 3 questions about dyspnea severity. Each of them can be assessed individually or the 3 combined to increase measurement precision into a dyspnea severity domain score.

次要结局

  • Health related quality of life(12 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Edward Harry Livingston

Professor of Surgery

University of California, Los Angeles

相似试验

Gastric Sleeve-Induced Weight Loss on Shortness of... | 临床试验